Meeting
2023 ASCO Genitourinary Cancers Symposium
CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).
Authors
Matthew Raymond Smith
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
Matthew Raymond Smith , Nobuaki Matsubara , Rana R. McKay , Josep M. Piulats , Tilman Todenhöfer , Tian Zhang , Nicolas Fasnacht , Sarah Sherwood , Erica L. Johnston , Clare Schaverien , Andrew Lithio , Karim Nacerddine , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05288166
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS289)
DOI
10.1200/JCO.2023.41.6_suppl.TPS289
Abstract #
TPS289
Poster Bd #
Q11
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
First Author: Sara M. Tolaney
Poster
2022 ASCO Annual Meeting
postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.
First Author: Kevin Kalinsky
Poster
2022 ASCO Annual Meeting
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.
First Author: Elgene Lim
Poster
2022 ASCO Genitourinary Cancers Symposium
CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
First Author: Matthew Raymond Smith